Preliminary results show that, while Lagevrio hastened the time to recovery from COVID-19 by around six days, it was no better than placebo at keeping patients out of hospital.
Merck & Co has said it will ask the EMA’s human medicines committee (CHMP) to look again at a decision not to recommend approval of its antiviral Lagevrio for treating some people with COVID-19.
Hosted on MSN2mon
Chinese pet owners turn to COVID-19 drugs to battle cat disease FIPCat owners in China desperate to save their beloved cats are using human COVID-19 drugs like Merck’s Lagevrio to treat Feline Infectious Peritonitis (FIP)—a deadly disease in cats that earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results